



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/720,448

11/24/2003

James McSwiggen

03-465-B (400.138)

4875

65778

7590

12/10/2009

MCDONNELL, BOEHNEN, HULBERT AND BERGHOFF, LLP
300 SOUTH WACKER DRIVE
SUITE 3100
CHICAGO, IL 60606

EXAMINER

BOWMAN, AMY HUDSON

ART UNIT

PAPER NUMBER

1635

MAIL DATE

DELIVERY MODE

12/10/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/720,448	Applicant(s) MCSWIGGEN ET AL.	
	Examiner AMY BOWMAN	Art Unit 1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 18 September 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 52-56 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 52-56 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicant's response filed 9/18/09 has been considered. Rejections and/or objections not reiterated from the previous office action mailed 5/22/09 are hereby withdrawn. The following rejections and/or objections are either newly applied or are reiterated and are the only rejections and/or objections presently applied to the instant application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Newly added claims 52-56 are pending in the application.

Applicant's amendments and/or arguments filed on 9/18/09, with respect to the rejections under 35 USC 112 have been considered and are persuasive. Therefore, these rejections have been withdrawn. However, the rejection under 35 USC 103 is pending as explained below.

Priority

Applicant's claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) or 120 as follows:

The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent

Art Unit: 1635

application and in the later-filed application must be sufficient to comply with the requirements of the first paragraph of 35 U.S.C. 112. See *Transco Products, Inc. v. Performance Contracting, Inc.*, 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994).

The disclosure of the prior-filed applications fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. 112 for one or more claims of this application. Application 60/358580 does not teach the following limitations: the sense and antisense strands each comprise 10 or more 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, or universal base modifications. The priority document does not each teach these elements in combination with the structural elements of claims 53-56.

Applicant pointed to support for each of the instant claim limitations in PCT/US03/05346 and 60/408,378. Therefore, the instant claims are accorded an effective filing date of 9/5/02, the filing date of application 60/408,378.

The passage that application pointed to on pages 9 and 10 of application 60/358,580 does not disclose "10 or more" of each of the instant modifications, but rather discloses one or more of each.

Should applicant disagree, applicants are encouraged to point out with particularity by page and line number where such support might exist for each claim limitation in each of the claimed priority documents specifically in the combined context as claimed.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 52-56 are rejected under 35 U.S.C. 103(a) as being unpatentable over Elbashir et al. (The EMBO Journal, 2001, Vol. 20, No. 23, pages 6877-6888), in view of Nyce (WO 99/13886), Parrish et al. (Molecular Cell, Vol. 6, pages 1077-1087, 2000), Matulic-Adamic et al. (US 5,998,203), Bertrand et al. (Biochemical and Biophysical Research Communications, 2002, 296, pages 1000-1004), Braasch et al. (Biochemistry, 2002, Vol. 41, No. 14, pages 4503-4510), and Olie et al. (Biochimica et Biophysica Acta, 2002, 1576, pages 101-109).

The instant claims are directed to a siRNA molecule having a sense and an antisense strand wherein each strand comprises 10 or more 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, or universal base modified nucleotides and the sense strand comprises a terminal cap at one or both ends. The claims are further directed to 10 or more pyrimidines of the sense strand, antisense strand, or both being 2'-deoxy, 2'-O-methyl, or 2'-deoxy-2'-fluoro; the sense and/or antisense strand comprises phosphorothioates, and to a composition comprising the siRNA molecule and a pharmaceutically acceptable carrier.

Elbashir et al. teach siRNAs, wherein each strand is 21-23 nucleotides in length and wherein at least 19 nucleotides of the sense strand are complementary to the

Art Unit: 1635

antisense strand. The siRNAs taught by Elbashir et al. mediated RNAi via RISC.

Elbashir et al. teach chemical modification with 2'-deoxy or 2'-O-methyl modifications.

Elbashir et al. teach modification of 19% of the nucleotides of a duplex 21 nucleotides in length with 2'-deoxy modifications that retained activity.

Elbashir et al. teaches that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA function (see page 6886, column 2); modifying terminal nucleotides (see page 6881), meeting the instant limitation of a terminal cap; the siRNA molecules comprise ribonucleotides (see Fig. 1, for example); duplexes of 21 nt siRNAs with 2 nt 3'-overhangs were the most efficient triggers of sequence-specific mRNA degradation (see abstract, for example); modification of the overhangs (see page 6881); wherein the siRNA is in a composition with a pharmaceutically acceptable diluent, such as buffer (see Materials and methods, page 6886).

Elbashir et al. do not teach double stranded nucleic acid molecules with combinations of modifications at the instant number of positions and do not teach phosphorothioates.

Elbashir et al. do not teach 2'-deoxy-2'-fluoro modifications, although the claims do not require such, as this is just one species of the genus.

Nyce teaches antisense oligonucleotides that attenuate the expression of target mRNA. The oligonucleotides are preferably up to about 30 nucleotides in length, more preferably up to about 21 nucleotides in length (see page 16). Nyce teaches antisense oligonucleotides targeted specifically to human muscarinic acetylcholine receptor 3 (CHRM3) (see page 54). Nyce teaches phosphorothioate, 2'-deoxy and 2'-O-methyl

Art Unit: 1635

modification of the oligonucleotides at various percentages of the purine and/or pyrimidine residues, including 100% substitution (see page 73) for enhancing the uptake of the oligonucleotides. The 100% substituted oligonucleotide comprises a phosphorothioate at the 3' end. Nyce teaches compositions comprising the oligonucleotide and a pharmaceutically acceptable carrier (see page 77). Nyce teaches surfactants or surfactant components bound to the 5' and/or 3' ends or the oligonucleotides for enhancing uptake of the oligonucleotide (see page 80).

Matulic-Adamic et al. teach chemical modifications of double stranded nucleic acid structures. The enzymatic RNA molecules of Matulic-Adamic et al. are taught to be targeted to virtually any RNA transcript and achieve efficient cleavage (see column 1) and to be sufficiently complementary to a target sequence to allow cleavage. Matulic-Adamic et al. teach the incorporation of chemical modifications at the 5' and/or 3' ends of the nucleic acids to protect the enzymatic nucleic acids from exonuclease degradation, which improves the overall effectiveness of the nucleic acid, as well as facilitates uptake of the nucleic acid molecules (see column 2). Matulic-Adamic et al. teach base, sugar and/or phosphate modification, as well as terminal cap moieties at the 5'-cap, 3'-cap, or both. Specifically, 3' phosphorothioates, inverted abasic moieties, and 2'-O-methyl modifications are utilized. Matulic-Adamic et al. teach 2'deoxy nucleotides and 2'-deoxy-2'-halogen nucleotides, wherein Br, Cl and F are representative halogens (see column 3, for example). For example, figure 3 contains a ribozyme structure that encompasses modification of at least 20%, at least 30%, at least 40% or at least 50% of the nucleotide positions, as well as the modifications instantly

Art Unit: 1635

claimed. The modifications can be in one or both of the strands and can be modifications of different types within the same structure.

Parrish et al. teach a chemically synthesized siRNA molecule, wherein each strand is 26 bp in length. Additionally, Parrish et al. teach a 742 nt long dsRNA with complete modification with 2'-fluorouracil modifications. However, it is noted that the instant claims do not recite any upper length limitation. Furthermore, the extensively modified dsRNA of Parrish et al. resulted in strong RNAi activity.

Bertrand et al. teach a comparison of antisense oligonucleotides and siRNAs. Bertrand et al. teach that siRNAs appear to be quantitatively more efficient with a longer lasting effect *in vitro* than antisense oligonucleotides. Bertrand et al. teach that siRNA activity, but no antisense oligonucleotide activity, was observed in mice, probably due to the lower resistance to nuclease degradation of antisense oligonucleotides (see abstract). Bertrand et al. teach that siRNAs are composed of small double-stranded RNA oligonucleotides with a length of 21/22 bases (see page 1000, column 1). Bertrand et al. teach that delivery is a very similar issue for both approaches and that siRNAs are very promising tools for gene inhibition *in vivo* (see page 1000, column 2).

Braasch et al. teach that the need for antisense oligomers that are more potent and more selective has been widely recognized and has led to the development of chemical modifications to improve binding and selectivity (see page 4503). Braasch et al. teach goals for improving oligonucleotides including: improve pharmacokinetics, tissue distribution, and targeting; characterize the mechanism of RNA interference and its full potential for inhibition of gene expression for cell culture studies; use RNAi for in

Art Unit: 1635

vivo inhibition of mammalian gene expression; perform comparative studies to demonstrate the relative strengths of different oligomer chemistries for given applications (i.e. morpholino versus RNAi) (see Table 2). Braasch et al. teach that if good *in vivo* uptake can be achieved, RNAi might significantly improve the ability of oligonucleotides to have an impact (see page 4509).

Olie et al. teach that gapmer oligonucleotide chemistry, wherein three distinct regions are present, has provided antisense oligonucleotides with increased efficacy and reduced non-antisense-related toxicity. Olie et al. added chemical modifications to ribonucleotides at either of the two ends of an oligonucleotide sequence, or the center region together with different combinations of phosphodiester/phosphorothioate backbones and investigated the effect on the activity of antisense oligonucleotides. The gapmer oligonucleotide exhibited a potent bispecific antisense activity. Olie et al. teach that gapmer chemistry is an optimal format and that these findings may have implications for the design and development of antisense oligonucleotides. Olie et al. teach that 2'-O-modifications provide additional nuclease resistance to oligonucleotides. Olie et al. teach synthesis of 20-mer chimeric antisense oligonucleotides.

It would have been obvious to synthesize a siRNA with the structural characteristics taught by Elbashir et al. with modifications within the instant genus and wherein 10 or more pyrimidines are modified with the instant modifications.

Furthermore, it would have been obvious to incorporate each of the instant types of chemical modifications or combinations of chemical modifications, as each of the types of modifications are taught by Elbashir et al., Matulic-Adamic et al., or Parrish et

Art Unit: 1635

al. to enhance nucleic acid inhibitory molecules.

It would have been obvious to incorporate the modifications differentially between purines or pyrimidines because the genus of possible places to incorporate the known modifications is very small (pyrimidine or purine). When incorporating modifications in nucleic acids, the modifications are incorporated into a purine or a pyrimidine. Given that the modifications were known in the art to benefit nucleic acid stability, and it was known to incorporate the same modifications from antisense/ribozyme technology into siRNAs, wherein the only possible places to incorporate the modifications is on a purine or a pyrimidine, it would have been obvious to incorporate the instant modifications into at least 10 nucleotides of the sense strand or twenty nucleotides of the antisense strand in combination with the specific modification of 10 or more pyrimidines and this is considered within the realm of routine optimization.

One would have been motivated to synthesize a siRNA molecule, as taught by Elbashir et al., Nyce teaches antisense oligonucleotides and teaches modifications thereof (phosphorothioate, 2'-deoxy and 2'-O-methyl modification of the oligonucleotides at various percentages of the purine and/or pyrimidine residues, including 100% substitution (see page 73)) for enhancing the uptake of the oligonucleotides. Therefore, one would have been motivated to incorporate the same types of modifications into a siRNA for the same purpose of enhancing uptake of the molecule, especially given that Bertrand et al. teach a comparison of antisense oligonucleotides and siRNAs and teach that siRNAs appear to be quantitatively more efficient with a longer lasting effect *in vitro* than antisense oligonucleotides.

Art Unit: 1635

Furthermore, Bertrand et al. teach that siRNA technology can be applied in the same delivery situations that have been previously studied with antisense oligonucleotides.

One would have been motivated to incorporate 2'-deoxy-2'-fluoro modifications, as taught by Parrish et al. or Matulic-Adamic et al., as well as 2'-O methyl, 2'-deoxy modifications, and phosphorothioates, as taught by Matulic-Adamic et al., as each of these chemical modifications, as well as various combinations of chemical modifications, were known in the art to protect nucleic acids from exonuclease degradation and enhance the activity of nucleic acids, as taught by Matulic-Adamic et al. One would have been motivated to incorporate the modifications on purines or pyrimidines as a matter of optimization of the activity of the siRNA, given there are only two choices.

As explained in the rejection under 35 USC 112 above, the instant genus is huge. It is considered that there would be some configuration of the chemical modifications that were known in the art to benefit other nucleic acid molecules such as antisense oligonucleotides or ribozymes that would retain RNAi activity when incorporated into nucleic acid molecules. Due to the breadth of the instant claims, the teachings of Elbashir et al. are considered to be motivation with regards to extensively modifying nucleic acid duplexes to optimize the activity therein. Although Elbashir et al. teach that 100% modification of one or both strands with 2'-deoxy or 2'-O-methyl modifications abolished activity, there are no instant claims that are identical in scope to the teachings of Elbashir et al. Therefore, within the huge genus of molecules that are being instantly claimed, the teachings of Elbashir et al. are considered to offer

Art Unit: 1635

motivation to test various types of known chemical modifications at different percentages in order to optimize the activity of the molecule.

It is noted that ribozymes are sequence specific inhibitory nucleic acid molecules that rely on activity with a complex secondary structure. Although ribozymes are faced with the complexity of structure, it is well known in the nucleic acid art to incorporate extensive levels of chemical modification to enhance the activity of the molecule and to specifically incorporate each of the instantly recited modifications, as evidenced by Matulic-Adamic et al.

The instant specification discloses a multitude of oligonucleotide and ribozyme art regarding chemical modifications and teaches that "Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into nucleic acid molecules without modulating catalysis, and are incorporated by reference herein. In view of these teachings, similar modifications can be used as described herein to modify the siNA nucleic acid molecules of the instant invention so long as the ability of siNA to promote RNAi in cells is not significantly inhibited." (see pages 109-110).

It is acknowledged that the specification is not to be relied upon for a source of motivation and that is not considered to be the instant case. The specification is merely being relied upon to distinguish that applicant recognized that double stranded nucleic acid modification is dependent upon the state of the art of oligonucleotides and ribozymes and that previously beneficial chemical modifications would be used with double stranded nucleic acid molecules as well.

Furthermore, Braasch et al. teach that the need for antisense oligomers that are more potent and more selective has been widely recognized and has led to the development of chemical modifications to improve binding and selectivity. Braasch et al. further recognize that goals to improve RNAi can be accomplished by utilizing chemical modifications. Since Braasch et al. teach that chemical modifications yield more potent and more selective antisense oligomers, such as oligomers for RNAi, and Elbashir et al., Matulic-Adamic et al., and Parrish et al. teach modified double stranded nucleic acid molecules that inhibit target gene expression, the gene expression of Elbashir et al. and Parrish et al. being inhibited by RNAi, one would have been motivated to synthesize duplexes with different levels of modifications to optimize the activity of the molecule.

Additionally, antisense oligonucleotides, ribozymes, and dsRNAs are each commonly used for sequence-specific mRNA knockdown and each of these encounters the same problems for effective application. Therefore, one would have been motivated to utilize the same modifications and techniques that have been utilized to overcome these problems with antisense oligonucleotides or ribozymes with siRNAs to add the same benefits to RNAi technology.

For example, Olie et al. teach that gapmer oligonucleotide chemistry, wherein three distinct regions are present, has provided antisense oligonucleotides with increased efficacy and reduced non-antisense-related toxicity. Olie et al. teach that combinations of different modifications at different regions of the oligonucleotide have been tested in order to optimize oligonucleotide activity. Olie et al. teach stepwise

Art Unit: 1635

experimentation of modifications throughout oligonucleotides in order to find the optimal configuration. Olie et al. is relied upon as evidence that it is common to experiment with different known modifications at different locations to optimize oligonucleotide activity.

Therefore, one would have been motivated to apply such a method to incorporate known modifications at various locations and amounts, as taught by Olie et al., into the siRNA duplexes that were synthesized by Elbashir et al.

Finally, one would have a reasonable expectation of success given that each of the modifications were known in the art at the time the invention was made to add benefits to antisense oligonucleotides, ribozymes or siRNA duplexes, as evidenced by Elbashir et al., Nyce, Matulic-Adamic et al., Parrish et al. and Olie et al., wherein each of the molecules face similar delivery challenges, and each of which can be improved with modifications, as evidenced by Braasch et al. Since Olie et al. teach effectively walking modifications across antisense oligonucleotides to optimize the combination of modifications as well as the location of the modifications and Elbashir et al. and Parrish et al. teach successfully synthesizing modified double stranded nucleic acid molecules, one would reasonably expect for modifications at various percentages to benefit the double stranded nucleic acid molecules of Elbashir et al.

Since Elbashir et al., Matulic-Adamic et al., and Parrish et al. teach extensive modification of double stranded nucleic acid molecules and Olie et al. teach experimentally determining optimal locations and levels of modification of antisense oligonucleotides, incorporating the modifications at various percentages in the double stranded nucleic acid molecules of Elbashir et al. is considered within the realm of

Art Unit: 1635

routine optimization.

It is noted that Elbashir et al. teach that 100% modification of one or both strands with 2'-deoxy or 2'-O-methyl modifications abolished activity. However, regardless of the results of these specific modifications at 100% of the positions of one or both strands, Elbashir et al. did modify duplexes and published data regarding successful inhibition with some duplexes and unsuccessful inhibition with others, supporting that testing of such known chemical modifications is routine in the art. The results of Elbashir et al. are considered to offer motivation to incorporate chemical modifications at various percentages to optimize the activity of the duplex because not all modifications result in activity at every percentage.

Thus in the absence of evidence to the contrary, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made.

Response to Arguments--Claim Rejections - 35 USC § 103

Applicant argues the priority date of the instant claims, which has been addressed in the priority section above.

Applicant argues that since the office has recognized the high degree of unpredictability with regards to extensively modified duplexes that remain active, this unpredictability can no be reconciled with the finding of obviousness in the instant claims. Applicant's conclusion is erroneous because there is certainly a high degree of unpredictability given the instant claim breadth, however it remains within the technical

Art Unit: 1635

grasp of the skilled artisan and within the realm of routine optimization to combine the known modifications of the prior art into various combinations and to expect to arrive at molecules with some degree of inhibitory activity within the instant broad genus of molecules having varying degrees of modification with various possible combinations of modifications.

Although applicant asserts that the instant claims require specific combinations of modifications at specific positions, the instant claims recite multiple types of modifications that can be incorporated alone or in various combinations with other modifications, rather than any one specific combination of modifications that have shown some unexpected property. Furthermore, the only positions that are specified are purines vs pyrimidines, of which there are only two choices for the skilled artisan to incorporate modifications at. The claims are not directed to any specific target sequence and therefore the incorporation at purines or pyrimidines varies depending on the specific target sequence. Therefore, each of these elements is variable rather than directed to a specific configuration as asserted by applicant.

Applicant continues to argue the interpretation of the Elbashir et al. reference. Again, Elbashir et al. is silent as to modification between the 19% successful and 100% modification with specific types of modifications alone that abolished activity. Therefore, the 100% modification is the “more extensively” modified referred to by Elbashir et al. Applicant is interpreting more extensive as referring to between 19% and 100%, although this is not consistent with the data set forth by Elbashir et al. Elbashir et al. in no way teaches away from the instant claims, which are not commensurate in scope

Art Unit: 1635

with the 100% modified duplexes that were inactive of Elbashir et al. Elbashir et al. offers motivation to incorporate modifications to reduce the cost of RNA synthesis and to enhance RNase resistance of siRNA duplexes (see page 6885, column 1). The fact that Elbashir et al. is silent as to modification between 19% and 100% would in fact motivate the skilled artisan to modify more extensively than the 19% to optimize the activity/stability balance. Although applicant asserts that the office is picking and choosing parts of the Elbashir et al. reference, it appears that applicant is doing such, as the examiner has read the document as a whole and refuses to rely upon anything other than the data set forth by Elbashir, which is specific to 19% or 100% modification.

With regards to Parrish, applicant asserts that although Parrish teaches 2'-deoxy-2'-fluoro uridines as compatible with RNAi, Parrish does not suggest cytidine modification or modification to short RNA duplexes. It is noted that applicant is arguing a limitation that is not in the claims, as the claims are not directed to cytidine modification. Furthermore, the 2'-deoxy-2'-fluoro uridine modification represents a dsRNA that was extensively modified and acted via RNAi. There is no reason to expect that shorter dsRNAs, wherein Parrish itself teaches that duplexes 26bp in length act via RNAi, would not remain active with the same modification, particularly given that the long dsRNA of Parrish was necessarily cleaved via Dicer in the cell into short siRNA molecules in order to be loaded into RISC and be active. Applicant's assertion regarding Parrish teaching away from 2'-deoxy modifications is completely unfounded given that Parrish specifically teaches 2'-deoxy incorporation with strong RNA interference activity.

Regarding Matulic-Adamic et al., clearly the stem duplex of a ribozyme is double-stranded. The examiner has not asserted that ribozymes and siRNAs have the same structure at all, but rather that ribozymes, antisense oligonucleotides, and siRNAs are each sequence specific inhibitors of target gene expression that have each utilized the same types of chemical modifications to enhance the stability of each of the molecules in the presence of nucleases. Although each of the molecules act via different mechanisms, they each face similar delivery challenges and those skilled in the art have routinely utilized modifications from one of the technologies with the other technologies, given that routine optimization is needed to arrive at specific patterns that yield active molecules for each type of inhibitory molecule. Again, the instant claims are not directed to any specific pattern that is stationary from target sequence to target sequence that has shown some sort of unexpected property. Within the instant genus, one would certainly expect to arrive at active molecules via combining modification types that were known to enhance the stability of nucleic acid inhibitory molecules at varying numbers of positions.

Applicant argues that the office selectively cited the instant modifications as taught by Nyce, although Nyce teaches many other types of modifications as well. Clearly, the examiner is only required to cite art as applicable to the instant claims. Nyce is not required to only teach the instant modifications in order for the instant modifications to be obvious.

The references collectively set forth that each of the instant types of chemical modifications were routinely incorporated into various types of inhibitory nucleic acid

Art Unit: 1635

molecules (ribozymes, antisense, dsRNA, or siRNA molecules); that it was known to utilize the same types of chemical modifications from one nucleic acid chemistry to the other, as each faces similar delivery challenges; it was known to optimize such molecules via testing different combinations or locations of incorporation; and it was known to target genes in a sequence specific fashion. The modifications of Parrish et al. are specific to pyrimidines. Furthermore, as explained in the rejection under 35 USC 103(a) above, there are a finite number of choices for positions of incorporation (purine or pyrimidine).

The majority of applicant's arguments appear to be upon the assumption that the instant claims are closed to a specific pattern. However, this is not the case. Although applicant asserts that a specific pattern is being claimed, the instant genus is very large, wherein applicant has not demonstrated any unexpected property of such a large genus given the motivation in the prior art to incorporate the same types of modifications, wherein the modifications would necessarily need to be incorporated into purines or pyrimidines.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir.

Art Unit: 1635

1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 52-56 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 12/170,290. Although the conflicting claims are not identical, they are not patentably distinct from each other because each of the claim sets are directed to double stranded nucleic acid molecules with overlapping structural characteristics (sizes, modifications, compositions, etc.). The double stranded short interfering nucleic acid molecules of the claims of application '290 are specific for a BACE gene, which anticipates the instant genus of any target.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 52-56 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 12/185,652. Although the conflicting claims are not identical, they are not patentably distinct from each other because each of the claim sets are

Art Unit: 1635

directed to double stranded nucleic acid molecules with overlapping structural characteristics (sizes, modifications, compositions, etc.). The double stranded short interfering nucleic acid molecules of the claims of application '652 are specific for a human c-Fos RNA sequence, which anticipates the instant genus of any target.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 52-56 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 12/204,572. Although the conflicting claims are not identical, they are not patentably distinct from each other because each of the claim sets are directed to double stranded nucleic acid molecules with overlapping structural characteristics (sizes, modifications, compositions, etc.). The double stranded short interfering nucleic acid molecules of the claims of application '572 are specific for a human ECGF1 RNA sequence, which anticipates the instant genus of any target.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 52-56 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 12/203,055. Although the conflicting claims are not identical, they are not patentably distinct from each other because each of the claim sets are

Art Unit: 1635

directed to double stranded nucleic acid molecules with overlapping structural characteristics (sizes, modifications, compositions, etc.). The double stranded short interfering nucleic acid molecules of the claims of application '055 are specific for a human VCAM-1 RNA sequence, which anticipates the instant genus of any target.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 52-56 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 12/200,736. Although the conflicting claims are not identical, they are not patentably distinct from each other because each of the claim sets are directed to double stranded nucleic acid molecules with overlapping structural characteristics (sizes, modifications, compositions, etc.). The double stranded short interfering nucleic acid molecules of the claims of application '736 are specific for a Cyclin D1 RNA sequence, which anticipates the instant genus of any target.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 52-56 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 12/203,731. Although the conflicting claims are not identical, they are not patentably distinct from each other because each of the claim sets are

Art Unit: 1635

directed to double stranded nucleic acid molecules with overlapping structural characteristics (sizes, modifications, compositions, etc.). The double stranded short interfering nucleic acid molecules of the claims of application '731 are specific for a human CHRM3 RNA sequence, which anticipates the instant genus of any target.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 52-56 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 12/204,612. Although the conflicting claims are not identical, they are not patentably distinct from each other because each of the claim sets are directed to double stranded nucleic acid molecules with overlapping structural characteristics (sizes, modifications, compositions, etc.). The double stranded short interfering nucleic acid molecules of the claims of application '612 are specific for a human MMP13 RNA sequence, which anticipates the instant genus of any target.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 52-56 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-20 of copending Application No. 12/175,367. Although the conflicting claims are not identical, they are not patentably distinct from each other because each of the claim sets are

Art Unit: 1635

directed to double stranded nucleic acid molecules with overlapping structural characteristics (sizes, modifications, compositions, etc.). The double stranded short interfering nucleic acid molecules of the claims of application '367 are specific for a human HIF1 RNA sequence, which anticipates the instant genus of any target.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 52-56 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 129-138 of copending Application No. 10/444,853. Although the conflicting claims are not identical, they are not patentably distinct from each other because the conflicting claims are directed to double stranded nucleic acid molecules with substantially similar and overlapping structural characteristics, wherein the instant claims do not recite a target.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Applicant requests that the double patenting rejection be held in abeyance.

Conclusion

No claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMY BOWMAN whose telephone number is (571)272-0755. The examiner can normally be reached on Monday-Thursday 6:00 - 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tracy Vivlemore can be reached on (571) 272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1635

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

AMY BOWMAN
Primary Examiner
Art Unit 1635

/AMY BOWMAN/
Primary Examiner, Art Unit 1635

Application/Control Number: 10/720,448
Art Unit: 1635

Page 26